Greenwood Capital Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Greenwood Capital Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,938	Closed	-$488K	–	193
2018 Q4	$488K	Buy	3,938 +1,357	+53%	+$201K	0.13%	97
2018 Q3	$434K	Buy	2,581 +24	+0.9%	+$4.13K	0.09%	116
2018 Q2	$441K	Buy	2,557 +825	+48%	+$135K	0.1%	107
2018 Q1	$262K	Buy	+1,732	New	+$254K	0.06%	156
2015 Q1	–	Sell	-1,460	Closed	-$239K	–	162
2014 Q4	$239K	Sell	1,460 -600	-29%	-$99.6K	0.07%	128
2014 Q3	$331K	Sell	2,060 -825	-29%	-$127K	0.1%	95
2014 Q2	$424K	Buy	+2,885	New	+$400K	0.13%	96
2013 Q4	–	Sell	-2,267	Closed	-$208K	–	112
2013 Q3	$208K	Buy	+2,267	New	+$183K	0.07%	100

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Greenwood Capital Associates's JAZZ Position: Q1 2019 in Review

Greenwood Capital Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 3,938 shares — an estimated $488K sold.

Greenwood Capital Associates first reported a position in JAZZ in Q3 2013 and held it in 8 quarters. The position peaked at $488K in Q4 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Greenwood Capital Associates reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Greenwood Capital Associates sold 3,938 Jazz Pharmaceuticals shares in Q1 2019, an estimated $488K.
Greenwood Capital Associates first reported a position in Jazz Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Greenwood Capital Associates's Jazz Pharmaceuticals position peaked at $488K in Q4 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Greenwood Capital Associates's 13F filing for Q1 2019, filed 3 May 2019.